8O - Proffered Paper session 2

Date 26 February 2019
Event ESMO Targeted Anticancer Therapies Congress 2019
Session Proffered Paper session: New and early developments with new concepts
Topics Imaging
Presenter Danique Giesen
Citation Annals of Oncology (2019) 30 (suppl_1): i4-i9. 10.1093/annonc/mdz029
Authors D. Giesen1, L.N. Broer1, M.N. Lub-De Hooge2, I. Popova3, B. Howng3, O. Vasiljeva3, E.G..E. de Vries1, M. Pool4
  • 1Medical Oncology, University Medical Center Groningen, 9713 GZ - Groningen/NL
  • 2Clinical Pharmacy And Pharmacology, University Medical Center Groningen, 9713 GZ - Groningen/NL
  • 3CytomX Therapeutics Inc., Suite 400 - South San Francisco/US
  • 4Clinical Pharmacy And Toxicology, Leiden University Medical Center, 2333 ZA - Leiden/NL

Abstract

Immune checkpoint inhibiting antibodies have antitumor activity across several tumor types, but can also elicit immune-mediated adverse events (imAEs). CX-072 is an investigational antibody prodrug (Probody™ therapeutic), reactive to the murine and human programmed death-ligand 1 (PD-L1) immune checkpoint. CX-072 can be activated to a fully avid antibody by tumor-associated proteases that remove the masking peptides blocking the antigen-binding domain, which may limit peripheral PD-L1 binding and therefore imAEs. CX-072 was radiolabeled with zirconium-89 (89Zr) to study its biodistribution and tumor- versus lymphoid tissue-targeting properties using positron emission tomography (PET).